Faslodex 500mg Multiple Dose Tolerability Study in BC Patients

AstraZeneca20 enrolled

Overview

The primary objective of this study is to assess the tolerability of 500mg fulvestrant in postmenopausal women with hormone receptor positive, advanced or recurrent breast cancer

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Advanced Breast Cancer

Interventions

FulvestrantDRUG

500 mg intramuscular injection

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Provision of written informed consent * Postmenopausal woman who fulfils any one of the following criteria: * Histological or cytological confirmation of breast cancer * Estrogen receptor positive (ER+) or progesterone receptor positive (PgR+). Exclusion Criteria: * Having received any one of the following therapy for advanced or recurrent breast cancer * 2 or more regimens of hormonal therapy or immunotherapy or 2 or more regimens of chemotherapy, etc

Locations (5)

Research Site

Chiba, Japan

Research Site

Fukuoka, Japan

Research Site

Nagoyata, Japan

Research Site

Osaka, Japan

Research Site

Tokyo, Japan